Sprycel or Tasigna after failure of Gleevec in GIST – pro
Sprycel (dasatinib) is currently in trials for various types of sarcoma. Dasatinib, a small-molecule inhibitor of Src kinase activity, is a promising cancer therapeutic agent with oral bioavailability. Currently, dasatinib is approved for use in imatinib-refractory chronic myelogenous leukemia. The FDA also granted full approval of Sprycel for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with
Read more